How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
disease and pneumonia in adults, enrolling about 4,000 people across two age groups. By directly comparing VAX-31 head-to-head with both Capvaxive (PCV21) and Prevnar 20 (PCV20) across 31 serotypes and stringent immunogenicity endpoints, the trial is designed to test whether Vaxcyte can establish a best-in-class pneumococcal vaccine profile. Next, we'll examine how this Phase 3 start, especially the head-to-head design against current standards, shapes Vaxcyte's investment narrative. Outshine the giants: these 26 early-stage AI stocks could fund your retirement To own Vaxcyte, you really have to believe in one central idea: that VAX-31 can become a differentiated pneumococcal franchise despite the company's heavy losses and lack of revenue today. The OPUS Phase 3 start is an important validation step in that story, because it confirms FDA-aligned trial design and locks in a clear path toward a potential BLA, but it does not change the near term reality of high cash burn and no
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswire
- Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 2/2/26 - Form 8-K
- 1/30/26 - Form 424B5
- 1/29/26 - Form 424B5
- PCVX's page on the SEC website